Dr. Markowski on phase 3 trial of sabizabulin (VERU-111) in mCRPC

Video

Mark Christopher Markowski, MD, PhD, discusses a phase 3 trial exploring the novel oral cytoskeletal disruptor sabizabulin (VERU-111) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on at least 1 androgen receptor targeting agent. The study, which is currently recruiting (NCT04844749), was launched following positive phase 1b/2 data. Markowski, an assistant professor of Oncology at Johns Hopkins Medicine, was the lead study author on the phase 1b/2 study, data from which were shared at the 2021 ASCO Annual Meeting. (J Clin Oncol 39, 2021 [suppl 15; abstr 5056]. doi: 10.1200/JCO.2021.39.15_suppl.5056)

Related Videos
Dr. Jasmeet Kaur in an interview with Urology Times
Dr. Martin Voss in an interview with Urology Times
Dr. Jacqueline Brown in an interview with Urology Times
blurred clinic hallway
Dr. Dalia Kaakour in an interview with red Urology Times backdrop
Dr. Maria Teresa Bourlon in an interview with Urology Times
Dr. David Braun in an interview with Urology Times
Dr. Neeraj Agarwal in an interview with Urology Times
Dr. Saby George in an interview with Urology Times
Dr. Laura Bukavina in an interview with Urology Times
Related Content
© 2024 MJH Life Sciences

All rights reserved.